ReviewCancers2019
Sarcomatoid Dedifferentiation in Renal Cell Carcinoma: From Novel Molecular Insights to New Clinical Opportunities.
Review in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 38 citations in OpenAlex.
- Do patients with metastatic renal cell carcinoma obtain survival benefits from cytoreductive nephrectomy? A population-based study.Journal of cancer research and clinical oncology · 2023Trial
- Sarcomatoid Renal Cell Carcinoma: A Clinical Review.Diagnostics (Basel, Switzerland) · 2026Review
- Review
- Is there a minimum percentage of sarcomatoid component required to affect outcomes of localised renal cell carcinoma?BJU international · 2025Article
- [Undifferentiated and dedifferentiated renal cell carcinomas : Morphomolecular aspects and differential diagnosis in light of recent developments].Pathologie (Heidelberg, Germany) · 2025Article
- Unclassifiable Renal Cell Carcinoma With an Estimated 100% Sarcomatoid Component: A Case Report.Cureus · 2024Article
- Article
- Metastatic Kidney Cancer: Does the Location of the Metastases Matter? Moving towards Personalized Therapy for Metastatic Renal Cell Carcinoma.Biomedicines · 2024Review
- Targeting transforming growth factor-β1 by methylseleninic acid/seleno-L-methionine in clear cell renal cell carcinoma: Mechanisms and therapeutic potential.Cancer treatment and research communications · 2024Article
- Sarcomatoid renal cell carcinoma with an inferior vena cava tumor thrombus that was completely resected by robot-assisted laparoscopic radical nephrectomy after neoadjuvant therapy nivolumab plus ipilimumab: a case report.International cancer conference journal · 2024Article
- Sintilimab combined with axitinib in the treatment of advanced chromophobe renal cell carcinoma: a case report.Frontiers in oncology · 2024Article
- Comparison of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma with rhabdoid and sarcomatoid differentiations.Cancer medicine · 2023Article
- The Role of Cytoreductive Nephrectomy in Renal Cell Carcinoma with Sarcomatoid Histology: A Case Series and Review of the Literature.Current oncology (Toronto, Ont.) · 2022Review
- Tumor-immune microenvironment revealed by Imaging Mass Cytometry in a metastatic sarcomatoid urothelial carcinoma with a prolonged response to pembrolizumab.Cold Spring Harbor molecular case studies · 2022Article
- Renal cell carcinoma and viral infections: A dangerous relationship?World journal of nephrology · 2022Review
- Potential Use of CTCs as Biomarkers in Renal Cancer Patients.Life (Basel, Switzerland) · 2022Article
- Article
- Major pathological response after neoadjuvant immunotherapy in esophageal spindle cell carcinoma: A case report.Thoracic cancer · 2021Article
- Checking the Hippo in Sarcomatoid Renal Cell Carcinoma with Immunotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
- First-line axitinib therapy is less effective in metastatic renal cell carcinoma with spindle histology.Scientific reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcomatoid features in renal cell carcinoma (RCC) have long been associated with dismal prognosis and poor response to therapy, while biological mechanisms underpinning sarcomatoid dedifferentiation remained obscure. Several efforts have been conducted to break down the molecular profile of sarcomatoid RCC and investigate different targeted therapeutic approaches. Mutations enriched for in sarcomatoid RCC involve, notably,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.